Literature DB >> 18578516

Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.

Jason Xiang1, Zhao-Kui Wan, Huan-Qiu Li, Manus Ipek, Eva Binnun, Jill Nunez, Lihren Chen, John C McKew, Tarek S Mansour, Xin Xu, Vipin Suri, May Tam, Yuzhe Xing, Xiangping Li, Seung Hahm, James Tobin, Eddine Saiah.   

Abstract

11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) is the enzyme that converts cortisone to cortisol. Evidence suggests that selective inhibition of 11beta-HSD1 could treat diabetes and metabolic syndrome. Presented herein are the synthesis, structure-activity relationship, and in vivo evaluation of piperazine sulfonamides as 11beta-HSD1 inhibitors. Through modification of our initial lead 5a, we have identified potent and selective 11beta-HSD1 inhibitors such as 13q and 13u with good pharmacokinetic properties.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18578516     DOI: 10.1021/jm8004948

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

Review 1.  Crystal structures of 11β-hydroxysteroid dehydrogenase type 1 and their use in drug discovery.

Authors:  Mark P Thomas; Barry V L Potter
Journal:  Future Med Chem       Date:  2011-03       Impact factor: 3.808

2.  Discovery of HSD-621 as a Potential Agent for the Treatment of Type 2 Diabetes.

Authors:  Zhao-Kui Wan; Eva Chenail; Huan-Qiu Li; Manus Ipek; Jason Xiang; Vipin Suri; Seung Hahm; Joel Bard; Kristine Svenson; Xin Xu; Xianbin Tian; Mengmeng Wang; Xiangping Li; Christian E Johnson; Ariful Qadri; Darrell Panza; Mylene Perreault; Tarek S Mansour; James F Tobin; Eddine Saiah
Journal:  ACS Med Chem Lett       Date:  2012-11-23       Impact factor: 4.345

3.  Synthesis and pharmacological activities of some new 3-substituted-4-amino-5-mercapto-1,2,4-triazoles.

Authors:  Shobha R Desai; U Laddi; Rajani S Bennur; P A Patil; S Bennur
Journal:  Indian J Pharm Sci       Date:  2011-01       Impact factor: 0.975

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.